breast cancer
Conditions
Interventions
Group PR:The patient received 30 ml of 0.25% ropivacaine for ultrasound-guided pectoral nerve block
Group PD:The patient received 0.25% ropivacaine +1 µg/kg dexmedetomidine for a total of 30 ml of the drug for ultrasound-guided pectoral nerve block
Group PN:The patient received 0.25% ropivacaine + 20 mg nalbuphine for a total of 30 ml of drugs for ultrasound-guided pectoral nerve block
Sponsors
First Affiliated Hospital of He'nan University
Eligibility
Sex/Gender
Female
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: women aged 30 to 65 years with American Society of Anesthesiologists physical status I to II who were scheduled for unilateral breast tumour resection.
Exclusion criteria
Exclusion criteria: Regional blockade contraindications (infection, local anesthetic allergy, coagulopathy, use of anticoagulant drugs), the history of psychiatric illness and chronic pain, preexisting neuropathy involving the chest site, alcohol or opioids abusers, cardiopulmonary dysfunction, liver or renal impairment, morbid obesity (BMI >30 kg/m2).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to first request for rescue analgesia;opioid consumption at 24h after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Consumption of remifentanil during surgery;adverse events from postoperative 24h, such as nausia, vomiting;patient satisfaction rates for 24 hours after surgery;pain score at 4, 8, 12 and 24 h after surgery;Heart rate and mean arterial pressure were recorded preoperatively and after 15 minutes, 30 minutes, 45 minutes, 60 minutes, and end of the surgery;local anesthetic systemic toxicity (LAST); | — |
Countries
China
Contacts
Public ContactHong Daoxian
First Affiliated Hospital of He'nan University
Outcome results
None listed